← Back to Search

Contrast-enhanced MRI for Liver Lesions

N/A

Waitlist Available

Led By Vikas Kundra

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients with renal function (estimated glomerular filtration rate [eGFR] >= 30)

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 4 years

Awards & highlights

Study Summary

This trial uses MRI to look for non-cancerous and cancerous liver lesions, with contrast agents to help make the MRI images clearer.

Who is the study for?

This trial is for people who've had an abdominal MRI within the last 3 months and have a kidney function score (eGFR) of 30 or above. It's open to any disease type, but not for those with poor kidney function, allergies to IV contrast, pregnant women, or individuals with certain metal implants.Check my eligibility

What is being tested?

The study is testing how well contrast-enhanced MRI can spot liver lesions that are either benign (not cancer) or malignant (cancer). It uses two types of contrast agents - gadobutrol and gadoxetate disodium - to improve image clarity and assist in diagnosis.See study design

What are the potential side effects?

Potential side effects from the contrast agents include allergic reactions like itching or rash, headache, nausea, dizziness, changes in taste sensation, feeling hot or cold. Kidney issues could also occur especially if there's pre-existing kidney disease.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My kidney function is at a safe level for the trial.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 4 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 4 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Specificity of combining gadoxetate disodium and gadobutrol in diagnosing tumor lesions radiologically using magnetic resonance imaging (MRI)

Trial Design

1Treatment groups

Experimental Treatment

Group I: Diagnostic (contrast-enhanced MRI)Experimental Treatment3 Interventions

Patient receives each of these over one minute. For the gadoxetate disodium, dynamic imaging is performed immediately and imaging is performed at 20 minutes. For the gadobutrol, dynamic imaging is performed immediately.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Contrast-enhanced Magnetic Resonance Imaging

2005

Completed Phase 1

~320

Gadobutrol

FDA approved

Gadolinium

FDA approved

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor

2,966 Previous Clinical Trials

1,804,681 Total Patients Enrolled

22 Trials studying Liver Cancer

9,411 Patients Enrolled for Liver Cancer

National Cancer Institute (NCI)NIH

13,654 Previous Clinical Trials

40,933,053 Total Patients Enrolled

104 Trials studying Liver Cancer

26,668 Patients Enrolled for Liver Cancer

Vikas KundraPrincipal InvestigatorM.D. Anderson Cancer Center

5 Previous Clinical Trials

318 Total Patients Enrolled

Media Library

Contrast-enhanced Magnetic Resonance Imaging Clinical Trial Eligibility Overview. Trial Name: NCT02156739 — N/A

Liver Cancer Research Study Groups: Diagnostic (contrast-enhanced MRI)

Liver Cancer Clinical Trial 2023: Contrast-enhanced Magnetic Resonance Imaging Highlights & Side Effects. Trial Name: NCT02156739 — N/A

Contrast-enhanced Magnetic Resonance Imaging 2023 Treatment Timeline for Medical Study. Trial Name: NCT02156739 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you provide an overview of previous research conducted utilizing Contrast-enhanced Magnetic Resonance Imaging?

"Currently, 17 ongoing clinical trials for Contrast-enhanced Magnetic Resonance Imaging have yet to reach the final Phase 3 stage. Of these 67 locations offering this study, the majority are located in Montpellier and Occitanie."

Answered by AI

Is participation in this research endeavor still available to volunteers?

"According to the data published on clinicaltrials.gov, this study is not presently recruiting participants as it was last updated on 10th October 2022. However, there are still 3,399 other studies actively enrolling patients at the moment."

Answered by AI

What medical conditions have been most effectively treated with Contrast-enhanced Magnetic Resonance Imaging?

"Contrast-enhanced Magnetic Resonance Imaging is routinely employed to diagnose and treat conditions related to the breast, as well as other illnesses like internal contamination with curium, supravalvular aortic stenosis, and magnetic resonance angiography."

Answered by AI

What is the current enrolment of this clinical investigation?

"Unfortunately, no more participants are being sought for this trial. It was first advertised on October 13th 2014 and amended lastly on the 17th of October 2022. For those searching for further studies related to liver neoplasms, 3382 trials are actively recruiting patients whilst there are seventeen Contrast-enhanced Magnetic Resonance Imaging experiments that require volunteers."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions

2014. "Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02156739.

All > Liver Disease > Liver Cancer